1599440-13-7
Chemical Structure
Deruxtecan
Synonym(s): MC-GGFG-DXD
- CAS. Nr.: 1599440-13-7
- Formula:C52H56FN9O13
- Molecular Weight:1034.05
IUPAC Name: N-((S)-10-benzyl-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-1,6,9,12,15-pentaoxo-3-oxa-5,8,11,14-tetraazahexadecan-16-yl)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide
InChIKey: WXNSCLIZKHLNSG-MCZRLCSDSA-N
SMILES: O=C(C=CC1=O)N1CCCCCC(NCC(NCC(N[C@@H](CC2=CC=CC=C2)C(NCC(NCOCC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C48)=O)=O)=O)=O)=O)=O
Biological Activity: Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813)[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Deruxtecan | 99.84% | Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deruxtecan (GMP) | Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deruxtecan-d5 | 98.40% | Deruxtecan-d5 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deruxtecan-d4-1 | Deruxtecan-d4-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deruxtecan-d2 | 97.45% | Deruxtecan-d2 is the deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deruxtecan-d6 | Deruxtecan-d6 is the deuterium labeled Deruxtecan. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deruxtecan-d4 | Deruxtecan-d4 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.
- [2]. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46. [Content Brief]
